Zhejiang Sunflower Great Health Co., Ltd.'s (SZSE:300111) Business Is Trailing The Industry But Its Shares Aren't
With a price-to-sales (or "P/S") ratio of 8.1x Zhejiang Sunflower Great Health Co., Ltd. (SZSE:300111) may be sending bearish signals at the moment, given that almost half of all Semiconductor compani
Sunflower (300111.SZ): Net profit of 551,000 yuan for the first quarter reversed the year-on-year loss
Gelonghui, April 26 | Sunflower (300111.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 83.6929 million yuan, up 36.57% year on year; net profit attributable to shareholders of listed companies was 551,000 yuan, which turned a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 4391,000 yuan; basic earnings per share were 0.0004 yuan.
Sunflower (300111.SZ) announced its 2023 annual results, turning a loss into a profit of 21.7479 million yuan
Sunflower (300111.SZ) released its 2023 annual report. The company's revenue was 338 million yuan,...
Declining Stock and Decent Financials: Is The Market Wrong About Zhejiang Sunflower Great Health Co., Ltd. (SZSE:300111)?
It is hard to get excited after looking at Zhejiang Sunflower Great Health's (SZSE:300111) recent performance, when its stock has declined 27% over the past three months. However, the company's fund
Aiskai (300521.SZ) shareholders added Orange Qiandao No. 1 Fund and Yanfeng Sunflower No. 1 Fund reduced their holdings by only 200 shares
Ascay (300521.SZ) announced that the company received “...” from the Tiancheng Qiandao No. 1 Fund and the Yanfeng Sunflower No. 1 Fund
Sunflower (300111.SZ): Proposed joint investment with related parties to establish a project company
Gelonghui (300111.SZ) announced that based on the strategic planning and business development of Zhejiang Sunflower Health Technology Co., Ltd. (hereinafter referred to as “Company” or “Party A”), the company signed an investment cooperation agreement with Zhuhai Youying New Materials Investment Partnership (Limited Partnership) (hereinafter referred to as “Youying New Materials” or “Party B”) and 2495 Metal-based Ceramic Technology (Zhuhai Hengqin) Partnership (Limited Partnership) (hereinafter referred to as “2495” or “Party C”) on March 1, 2024》It is proposed to jointly invest in the establishment of a limited liability company (hereinafter referred to as the “Project Company”
Sunflower (300111.SZ) Currently, there is no risk of liquidation of shares pledged by the company's actual controller
Gelonghui, Feb. 2: Sunflower (300111.SZ) said on the investor interactive platform that there is currently no risk of closing the shares pledged by the company's actual controller.
Sunflower (300111.SZ): Termination of TopCon battery product project and cancellation of project company
Gelonghui, February 2, 丨 Sunflower (300111.SZ) announced that the company held the 25th meeting of the 5th board of directors and the 18th meeting of the 5th board of supervisors on February 2, 2024 to review and pass the “Proposal on Termination of Investment Cooperation Agreements and Cancellation of Project Companies”. The company worked with Shanghai Longxiang Private Equity Fund Management Co., Ltd. (hereinafter referred to as “Shanghai Longxiang”) and Shanghai Longhe Enterprise Management Center (limited partnership) (hereinafter referred to as “Shanghai Longxiang”), Shaoxing Binhai New Area Integrated Circuit Industry Equity Investment Fund Partnership (hereinafter referred to as “Shanghai Longxiang”) Called “Shaoxing Integrated Circuit Fund”), Zhejiang
Zhejiang Sunflower Great Health Co., Ltd.'s (SZSE:300111) Popularity With Investors Is Under Threat From Overpricing
With a price-to-sales (or "P/S") ratio of 8.9x Zhejiang Sunflower Great Health Co., Ltd. (SZSE:300111) may be sending bearish signals at the moment, given that almost half of all Semiconductor compani
Sunflower (300111.SZ) issued a pre-profit and is expected to have a net profit of 19 million yuan to 27 million yuan in 2023, turning a loss into a profit
Sunflower (300111.SZ) disclosed its 2023 annual results forecast. The company is expected to belong to shareholders of listed companies...
Sunflower (300111.SZ) shareholder Wu Jianlong pledges 74 million shares
Sunflower (300111.SZ) announced that Wu Jianlong, the shareholder of the company, held 74 million shares of the company (...
Wu Jianlong, shareholder of Sunflower (300111.SZ), lifted the pledge of 74 million shares
Sunflower (300111.SZ) issued an announcement. The company recently received a notice from shareholder Wu Jianlong and learned that Wu Jianlong will...
Ascay (300521.SZ): Dongtian Orange Qiandao No. 1 Fund and Yanfeng Sunflower No. 1 Fund each plan to reduce their holdings by no more than 1%
Gelonghui, January 10 | Ascay (300521.SZ) announced that the shareholders of each holding 7,200,000 shares of the company (5% of the company's total share capital), Shanghai Tiancheng Investment Management Co., Ltd. (“Tianzheng Qiandao No. 1 Fund”) and Shanghai Yanfeng Investment Management Co., Ltd. [Daiyanfeng Sunflower No. 1 Private Equity Investment Fund (“Yanfeng Sunflower No. 1 Fund”)] plan to pass centralized bidding within three months of 15 trading days from the date of the announcement of the reduction plan Reduce your holdings by trading in bulk No more than the company's shares 1,4
[BT Financial Report Instantaneous Analysis] Sunflower 2023 Quarterly Report: Balance Sheet Optimization, Net Profit Turned Loss into Profit
This financial report was announced on 2023-10-27 18:40:56 Sunflower Company (stock code: 300111) is an enterprise focusing on R&D, production and sales of pharmaceutical products. The company belongs to the C27 pharmaceutical manufacturing industry. Its main products include anti-infective drugs, cardiovascular drugs, and digestive system drugs. In terms of APIs, the company is in a leading position in clarithromycin API production, and sells its products to many domestic pharmaceutical manufacturers as well as Japan, the United States, India, South Korea, Pakistan and other countries. In terms of pharmaceuticals, the company's products are listed as national medicine
Sunflower (300111.SZ) released the first three quarter results, net profit of 239.321 million yuan, an increase of 258.01%
Sunflower (300111.SZ) released its report for the third quarter of 2023. The company's revenue for the first three quarters was 2...
Sunflower (300111.SZ): The holding subsidiary signs a contract termination agreement with Jiejia Weichuang
Glonghui September 28 | Sunflower (300111.SZ) announced that the holding subsidiary Zhejiang Longxiang New Energy Technology Co., Ltd. and Jiejia Weichuang signed a “Termination Agreement” on September 28, 2023. The TopCon battery product project is a prudent decision made by the company after thorough investigation and research on the development situation of the photovoltaic industry, mid-term trends, and the production plans of leading companies in the industry. However, during the project preparation process, there was a delay in delivery of the proposed leased plant, resulting in the TopCon battery product project not being implemented as scheduled. Furthermore, prices of major products in the photovoltaic industry chain have declined sharply recently. Subject to the above
Interpretation of the Sunflower 2023 Interim Report: Financial data has attracted attention, and asset appreciation is gaining momentum
According to Sunflower's 2023 interim report, the company's revenue was 150,328,233.20 yuan, an increase of 4.38% over 144,014,774.20 yuan in the same period last year. Net profit attributable to shareholders of listed companies was -11,643,694.34 yuan. Compared with -11,601,377.33 yuan in the same period last year, losses were basically the same and relatively stable. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -12,091,816.23 yuan, down 11 yuan from -10,850,055.75 yuan in the same period last year.
Some Shareholders Feeling Restless Over Zhejiang Sunflower Great Health Limited Liability Company's (SZSE:300111) P/S Ratio
Zhejiang Sunflower Great Health Limited Liability Company's (SZSE:300111) price-to-sales (or "P/S") ratio of 11.7x may look like a poor investment opportunity when you consider close to half the compa
Sunflower (300111.SZ): Net loss of 11.643,700 yuan in the first half of the year
GLONGHUI, August 25 | Sunflower (300111.SZ) announced its 2023 semi-annual report. Operating income for the reporting period was 150 million yuan, up 4.38% year on year; net profit attributable to shareholders of listed companies was -11.643,700 yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -1,20918 million yuan; basic earnings per share were -0.009 yuan.
Is Zhejiang Sunflower Great Health Limited Liability (SZSE:300111) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
No Data